Livestock Dewormers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Livestock Dewormers Market, valued at USD 7.9 billion in 2024, is projected to expand at a CAGR of 4.8% from 2025 to 2034. This growth is fueled by the increasing global demand for animal protein and dairy products, driven by population growth and urbanization. Rising meat and milk consumption necessitates effective herd health management to maximize productivity. Parasitic infestations in livestock significantly hinder growth and yield, emphasizing the critical role of dewormers in livestock healthcare. Stringent food safety regulations, government support for veterinary health, and growing awareness among farmers about the economic losses caused by parasitic infections are bolstering the market. Developing regions in Asia-Pacific, Latin America, and Africa are also contributing significantly, with expanding livestock populations and investments in veterinary infrastructure driving demand.
Livestock dewormers, or anthelmintics, target parasitic worms such as roundworms, tapeworms, and flukes in animals like cattle, sheep, goats, swine, and poultry. The cattle segment dominated the market, reaching USD 3.6 billion in 2024. Cattle-specific dewormers are in high demand due to the susceptibility of cattle to parasitic infections that affect growth, milk production, and overall health. The adoption of intensive farming practices and the growing emphasis on food safety further drive this segment's prominence.
By drug class, macrocyclic lactones held the largest market share at 41% in 2024. These compounds, known for their broad-spectrum efficacy and long-lasting action, are effective against internal parasites. Their versatility, combined with diverse formulations like injectables and pour-ons, ensures their widespread use across livestock species.
The market is also segmented by mode of purchase, with the over-the-counter (OTC) category gaining significant traction and expected to reach USD 8.4 billion by 2034. OTC dewormers are popular among farmers due to their accessibility, affordability, and ease of use. These products eliminate the need for veterinary prescriptions, offering cost-effective and convenient solutions for parasitic control.
Oral dewormers emerged as the preferred route of administration in 2024, driven by their ease of use and cost-effectiveness. Products such as tablets and powders allow efficient delivery of active ingredients without specialized equipment. Innovations like slow-release formulations further enhance their appeal.
Veterinary pharmacies are expected to grow at a CAGR of 4.4% from 2025 to 2034, serving as a vital distribution channel for deworming products. Their growth is attributed to increased awareness among farmers about regular deworming and the convenience of purchasing products with expert guidance.
In 2024, the US accounted for a significant share of the North American market, valued at USD 3.1 billion, due to its focus on livestock health and the prevalence of parasitic infections in animals.
Livestock dewormers, or anthelmintics, target parasitic worms such as roundworms, tapeworms, and flukes in animals like cattle, sheep, goats, swine, and poultry. The cattle segment dominated the market, reaching USD 3.6 billion in 2024. Cattle-specific dewormers are in high demand due to the susceptibility of cattle to parasitic infections that affect growth, milk production, and overall health. The adoption of intensive farming practices and the growing emphasis on food safety further drive this segment's prominence.
By drug class, macrocyclic lactones held the largest market share at 41% in 2024. These compounds, known for their broad-spectrum efficacy and long-lasting action, are effective against internal parasites. Their versatility, combined with diverse formulations like injectables and pour-ons, ensures their widespread use across livestock species.
The market is also segmented by mode of purchase, with the over-the-counter (OTC) category gaining significant traction and expected to reach USD 8.4 billion by 2034. OTC dewormers are popular among farmers due to their accessibility, affordability, and ease of use. These products eliminate the need for veterinary prescriptions, offering cost-effective and convenient solutions for parasitic control.
Oral dewormers emerged as the preferred route of administration in 2024, driven by their ease of use and cost-effectiveness. Products such as tablets and powders allow efficient delivery of active ingredients without specialized equipment. Innovations like slow-release formulations further enhance their appeal.
Veterinary pharmacies are expected to grow at a CAGR of 4.4% from 2025 to 2034, serving as a vital distribution channel for deworming products. Their growth is attributed to increased awareness among farmers about regular deworming and the convenience of purchasing products with expert guidance.
In 2024, the US accounted for a significant share of the North American market, valued at USD 3.1 billion, due to its focus on livestock health and the prevalence of parasitic infections in animals.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing livestock population
3.2.1.2 Rise in zoonotic diseases
3.2.1.3 Supportive government policies
3.2.2 Industry pitfalls and challenges
3.2.2.1 Anthelmintic resistance
3.2.2.2 Focus on organic and natural farming
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY ANIMAL TYPE, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Cattle
5.3 Swine
5.4 Poultry
5.5 Other animal types
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Benzimidazoles
6.3 Macrocyclic lactones
6.4 Imidazothiazoles
6.5 Other drug classes
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MODE, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 OTC
7.3 Prescription
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 Oral
8.3 Topical
8.4 Parenteral
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 Veterinary pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Boehringer Ingelheim
11.2 Bimeda
11.3 Ceva Sante Animale
11.4 Durvet
11.5 Elanco Animal Health
11.6 First Priority
11.7 Intas Pharmaceuticals
11.8 Jeffers
11.9 Manna Pro Products
11.10 Merck Animal Health
11.11 Phibro Animal Health
11.12 Virbac
11.13 Vetoquinol
11.14 Zoetis
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing livestock population
3.2.1.2 Rise in zoonotic diseases
3.2.1.3 Supportive government policies
3.2.2 Industry pitfalls and challenges
3.2.2.1 Anthelmintic resistance
3.2.2.2 Focus on organic and natural farming
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY ANIMAL TYPE, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Cattle
5.3 Swine
5.4 Poultry
5.5 Other animal types
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Benzimidazoles
6.3 Macrocyclic lactones
6.4 Imidazothiazoles
6.5 Other drug classes
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MODE, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 OTC
7.3 Prescription
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 Oral
8.3 Topical
8.4 Parenteral
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 Veterinary pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Boehringer Ingelheim
11.2 Bimeda
11.3 Ceva Sante Animale
11.4 Durvet
11.5 Elanco Animal Health
11.6 First Priority
11.7 Intas Pharmaceuticals
11.8 Jeffers
11.9 Manna Pro Products
11.10 Merck Animal Health
11.11 Phibro Animal Health
11.12 Virbac
11.13 Vetoquinol
11.14 Zoetis
